These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 28521079)

  • 21. CYP4F2 genetic variant alters required warfarin dose.
    Caldwell MD; Awad T; Johnson JA; Gage BF; Falkowski M; Gardina P; Hubbard J; Turpaz Y; Langaee TY; Eby C; King CR; Brower A; Schmelzer JR; Glurich I; Vidaillet HJ; Yale SH; Qi Zhang K; Berg RL; Burmester JK
    Blood; 2008 Apr; 111(8):4106-12. PubMed ID: 18250228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.
    Eriksson N; Wallentin L; Berglund L; Axelsson T; Connolly S; Eikelboom J; Ezekowitz M; Oldgren J; Paré G; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Yusuf S; Wadelius M
    Pharmacogenomics; 2016 Aug; 17(13):1425-39. PubMed ID: 27488176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.
    Chung JE; Chang BC; Lee KE; Kim JH; Gwak HS
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1229-36. PubMed ID: 26257249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dietary Vitamin K and Association with Hepatic Vitamin K Status in a Yup'ik Study Population from Southwestern Alaska.
    Au NT; Ryman T; Rettie AE; Hopkins SE; Boyer BB; Black J; Philip J; Yracheta J; Fohner AE; Reyes M; Thornton TA; Austin MA; Thummel KE
    Mol Nutr Food Res; 2018 Feb; 62(3):. PubMed ID: 29094808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats.
    Morishima Y; Kamisato C; Honda Y; Furugohri T; Shibano T
    Thromb Res; 2013 Jan; 131(1):59-63. PubMed ID: 22999414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting.
    Hart R; Veenstra DL; Boudreau DM; Roth JA
    Am J Med; 2017 Feb; 130(2):222-228. PubMed ID: 27593608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotype and risk of major bleeding during warfarin treatment.
    Kawai VK; Cunningham A; Vear SI; Van Driest SL; Oginni A; Xu H; Jiang M; Li C; Denny JC; Shaffer C; Bowton E; Gage BF; Ray WA; Roden DM; Stein CM
    Pharmacogenomics; 2014 Dec; 15(16):1973-83. PubMed ID: 25521356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired carboxylation of osteocalcin in warfarin-treated patients.
    Menon RK; Gill DS; Thomas M; Kernoff PB; Dandona P
    J Clin Endocrinol Metab; 1987 Jan; 64(1):59-61. PubMed ID: 2878010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses.
    Moon JY; Lee KE; Chang BC; Jeong E; Jeong H; Gwak HS
    Pharmacogenet Genomics; 2015 Jan; 25(1):38-40. PubMed ID: 25356900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.
    Zambon CF; Pengo V; Moz S; Bozzato D; Fogar P; Padoan A; Plebani M; Groppa F; De Rosa G; Padrini R
    Eur J Clin Pharmacol; 2018 May; 74(5):571-582. PubMed ID: 29396738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
    Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
    Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses.
    Chung JE; Lee KE; Chang BC; Gwak HS
    Gene; 2018 Jan; 641():68-73. PubMed ID: 29054760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PharmVar GeneFocus: CYP4F2.
    Zubiaur P; Rodríguez-Antona C; Boone EC; Daly AK; Tsermpini EE; Khasawneh LQ; Sangkuhl K; Duconge J; Botton MR; Savieo J; Nofziger C; Whirl-Carrillo M; Klein TE; Gaedigk A
    Clin Pharmacol Ther; 2024 Oct; 116(4):963-975. PubMed ID: 39135485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the pharmacogenetic approach to warfarin dosing.
    Glurich I; Burmester JK; Caldwell MD
    Heart Fail Rev; 2010 May; 15(3):239-48. PubMed ID: 18998206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
    Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
    J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.